Go Pro
NASDAQ:BRTX

Biorestorative Therapies Q2 2026 Earnings Report

Biorestorative Therapies logo
$0.14 -0.06 (-28.76%)
Closing price 09/3/2026 04:00 PM Eastern
Extended Trading
$0.14 +0.00 (+0.90%)
As of 06:53 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biorestorative Therapies EPS Results

Actual EPS
N/A
Consensus EPS
-$0.10
Beat/Miss
N/A
One Year Ago EPS
N/A

Biorestorative Therapies Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.60 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biorestorative Therapies Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Tuesday, September 8, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

Biorestorative Therapies Earnings Headlines

BioRestorative Therapies Announces Reverse Stock Split
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.tc pixel
See More Biorestorative Therapies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biorestorative Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biorestorative Therapies and other key companies, straight to your email.

About Biorestorative Therapies

Biorestorative Therapies (NASDAQ:BRTX) Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy. Biorestorative Therapies’ candidate has completed early-stage clinical evaluation and is advancing through planned trials to assess safety and efficacy in reducing the duration and severity of oral mucositis. Preclinical studies have also been conducted to explore additional indications, including inflammatory and degenerative conditions.

Headquartered in Malvern, Pennsylvania, Biorestorative Therapies manages its research, manufacturing and clinical development activities in the United States. The company works with clinical research organizations and academic centers to support its ongoing trials and maintains a leadership team with experience spanning cell therapy, clinical development and regulatory affairs. Biorestorative Therapies continues to pursue partnerships to expand its pipeline and accelerate the path to potential regulatory approval.

View Biorestorative Therapies Profile